3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Advanced Cancer
1
Interventions
ofatumumab
3
Vincristine
2
Rituximab
2
Lenalidomide
2
Bortezomib
2
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
nelarabine
1
immunotoxin HA22
1
fludarabine
1
bempegaldesleukin
1
Whole-Body Irradiation
1
Tablets
1
Panobinostat
1
Observation
1
Nivolumab
1
Mitoxantrone
1
Methotrexate
1
Mercaptopurine
1
Everolimus
1
Etoposide
1
Drug Therapy
1
Dexamethasone
1
DTRMWXHS-12
1
Cytarabine
1
Cyclophosphamide
1
Clofarabine
1
Cladribine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, B-Cell
×
Tablets
×
Clear all
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts